Akeso
Update in progress9926.HK (HKSE)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Akeso, Inc. is a biopharmaceutical company that discovers, develops, manufactures, and commercializes antibody therapies worldwide. Its pipeline includes AK104 (PD-1/CTLA-4 bispecific) for multiple cancers; AK112 (PD-1/VEGF bispecific); AK117 (CD47 mAb); AK109 (PD-1 mAb); penpulimab (PD-1); and tagitanlimab (PD-L1). It also develops AK102 (PCSK9), AK101 (IL-12/23), AK111 (IL-17), and AK120 (IL-4R). It partners with Inovio on INO-5412 for glioblastoma. Founded 2012, Zhongshan, China.
Company score
- Sentiment
- 0.52
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.38
- Governance
- 0.11
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.14
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.33
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!